Frederic Chereau - Mar 1, 2022 Form 4 Insider Report for LogicBio Therapeutics, Inc. (LOGC)

Role: President and Chief Executive, Director
Signature: /s/ Andrea Paul, as Attorney-in-Fact
Stock symbol: LOGC
Transactions as of: Mar 1, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/3/2022, 04:54 PM
Next filing: Nov 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LOGC	Stock Option (right to buy)	Award	$0	+328K		$0.00	328K	Mar 1, 2022	Common Stock	328K	$0.70	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options were granted by LogicBio Therapeutics, Inc. (the "Company") pursuant to its 2018 Equity Incentive Plan.
F2	The options will vest over four years: 25% of the options will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date.

Remarks:

Exhibit List: Exhibit 24.1 Power of Attorney